Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Formosa Optical Technology Co.,Ltd. (5312.TWO)
New Taipei City, TW
Formosa Optical Technology Co.,Ltd. is a dedicated supplier of vision care products across Taiwan. Their diverse portfolio features corrective eyewear such as prescription glasses and sunglasses, alongside a variety of contact lenses, including both clear and colored options. Additionally, the firm furnishes professional optometry equipment. The company, which was established in 1976, conducts its operations from its primary office located in New Taipei City, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.43% | +0.64% | -3.09% | -5.42% | -4.37% | -6.73% | -39.81% | +18.94% | +53.17% | +20.61% | +505.79% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+3.9% Q1'26: +12.3% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-22.2% Q1'26: -26.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+4.4% Q1'26: +8.2% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+7.2% Q1'26: +6.9% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+7.4% ★ Q1'26: +8.9% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-0.3% ★ Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×13.42× ★ Q1'26: 10.93× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Value ETF AVES | 0.00% | 38.7K | 0.36% |
| 2 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.00% | 2.8K | 0.42% |
| 3 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 27.9K | 0.46% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 119.9K | 0.39% |
| 5 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 55.5K | 0.28% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 44.5K | 0.29% |
| 7 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 63.3K | 0.33% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yi-Shan Cai | President and Director | 6M | female |
| Li Hui Chang | Chief Financial Officer & Accounting Supervisor | 3M | male |
| Chih-MIng Yeh | Deputy General Manager of Operations Management Department | 2M | male |
| Ji Sheng Yang | Marketing Manager | — | male |
| Ke Lun Zhou | Chief Human Resource Officer | — | male |
| Cheng-Chung Lee | Assistant Manager of Administration Office | — | male |
| Shih-Huang Chen | Assistant Manager of Information Office | — | male |
| Wei-Kai Tseng | Chief Auditor | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 5312.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
